C Michael Gibson/Baim Institute
Feb 7, 2026, 14:25
C Michael Gibson: Asundexian Reduces Ischemic Stroke Without Increasing Bleeding Risk
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Among patients with non-cardioembolic ischemic stroke or high-risk TIA treated with antiplatelet therapy, asundexian 50 mg reduced the occurrence of ischemic stroke (csHR 0.74; 95% CI, 0.65 to 0.84; p<0.001).
The difference between the treatment arms began early and continued throughout the treatment period.
A consistent effect was seen in subgroups.
Asundexian was associated with a reduction in disabling or fatal stroke (mRS ≥ 3)
Asundexian was not associated with an increase in bleeding Including ISTH major, CRNM, minor or intracranial bleeding.”
Stay updated with Hemostasis Today.
-
May 7, 2026, 16:53Patricio S. Espinosa: Anticoagulation Is Not an Absolute Contraindication to Amyloid Therapy
-
May 7, 2026, 16:34Arun V J: Give Blood and Be the Hero You Always Wanted to Be
-
May 7, 2026, 16:15August Bones: When Would You Consider Placing an Inferior Vena Cava Filter After a Pulmonary Embolism?
-
May 7, 2026, 15:58Stop Asking Doctors to Do More – Reimagining the Care Team – The US Oncology
-
May 7, 2026, 15:42Chokri Ben Lamine: CVC-Associated UE-DVT and Catheter Removal
-
May 7, 2026, 15:38Samwel Mikaye: Key Insights on Vitamin B12 Deficiency
-
May 7, 2026, 15:37Anika Islam: A ‘Normal’ Hemoglobin Doesn’t Mean Your Patient is Safe for Surgery
-
May 7, 2026, 15:36Ekomobong Sunday: If You are Pregnant and Always Tired, Read This
-
May 7, 2026, 15:35Osama Ramadan: Comprehensive Review – 75 UWorld Anemia and RBC Disorders Questions Solved